Published on 21/12/2025
How to Report SUSARs to Ethics Committees in Clinical Trials
Introduction: Why Ethics Committees Need SUSAR Reports
Suspected Unexpected Serious Adverse Reactions (SUSARs) are among the most important safety signals in clinical trials. While regulators such as the FDA, EMA, and MHRA require expedited reporting, ethics committees (ECs)—also called Institutional Review Boards (IRBs)—play an equally critical role. Ethics committees are tasked with protecting trial participants, and timely access to SUSAR data enables them to assess whether ongoing participation remains ethically justifiable.
Under ICH GCP E6(R2), sponsors and investigators must report safety information, including SUSARs, to ECs promptly. National frameworks vary, but the principle remains consistent: ECs must be kept informed of emerging risks to participants. This article provides a tutorial on SUSAR reporting to ethics committees, including timelines, documentation requirements, challenges, case studies, and best practices.
Regulatory Requirements for Ethics Committee SUSAR Reporting
Reporting SUSARs to ethics committees involves parallel processes alongside regulatory submissions:
- ICH E2A: Mandates expedited reporting of SUSARs to both regulators and ECs.
- FDA (US): Investigators must report unanticipated problems (including SUSARs) to IRBs promptly, often within 10 working days.
- EMA (EU): Sponsors must submit SUSAR reports to ethics committees via EudraVigilance gateways or national systems, depending
Ethics committees expect SUSAR reports to include not only CIOMS forms or equivalent but also narrative summaries and, where necessary, investigator letters outlining risk mitigation steps.
Content Required in Submissions to Ethics Committees
Ethics committees need sufficient information to evaluate risk-benefit balance. Typical submission packages include:
- Completed CIOMS form or equivalent SUSAR form.
- Narrative: Clear chronological description of event, clinical course, interventions, and causality rationale.
- Updated Investigator’s Brochure (IB): If new risks are identified.
- Investigator letter: Plain-language summary highlighting implications for ongoing participant safety.
- Protocol amendments: If emerging risks require changes in monitoring or exclusion criteria.
For example, in a vaccine trial, an ethics committee requested not only the CIOMS form but also a lay summary for non-medical EC members to fully understand implications of myocarditis cases.
Timelines for Reporting SUSARs to Ethics Committees
While regulatory timelines are harmonized (7 days for fatal/life-threatening SUSARs, 15 days for others), EC timelines vary:
- US IRBs: Typically require reports within 10 days of investigator awareness.
- EU RECs: Expect expedited submission aligned with EU-CTR rules.
- Asia-Pacific: Some countries allow up to 14 days, but most align with ICH guidance.
To avoid non-compliance, sponsors must establish SOPs that track and synchronize submissions to regulators and ECs. Many sponsors integrate electronic safety reporting systems to streamline dual submissions.
Case Studies on Ethics Committee SUSAR Reporting
Case Study 1 – Oncology Program: A fatal hepatic failure case was reported to regulators within 7 days but delayed to the EC for 20 days. During inspection, the sponsor received a critical observation for failure to inform the EC in time. Corrective actions included revising SOPs and creating real-time reporting workflows.
Case Study 2 – Vaccine Trial: Investigators reported cases of Guillain-Barré syndrome to regulators but provided insufficient narrative detail to ECs. The EC requested follow-up, delaying protocol approval for new cohorts. After implementing structured narrative templates, submissions improved and approvals were expedited.
Case Study 3 – Multinational Cardiovascular Trial: Some ECs required CIOMS forms only, while others demanded lay summaries and investigator letters. Sponsors created modular submission packages, ensuring flexibility for country-specific requirements.
Challenges in SUSAR Reporting to Ethics Committees
Key challenges include:
- Global variability: Different countries have distinct requirements for format, content, and timelines.
- Communication gaps: Sponsors sometimes prioritize regulators over ECs, leading to reporting delays.
- Volume of reports: In large trials, ECs may be overwhelmed with SUSARs, affecting timely review.
- Non-medical members: Ethics committees often include laypersons who require plain-language summaries.
These challenges underscore the need for harmonized SOPs, training, and clear communication strategies for SUSAR reporting to ethics committees.
Best Practices for Ethics Committee SUSAR Submissions
Sponsors and investigators can strengthen compliance by adopting best practices:
- Submit SUSARs to regulators and ECs simultaneously to avoid delays.
- Provide structured narratives highlighting seriousness, unexpectedness, and causality.
- Include lay summaries for non-medical EC members.
- Maintain submission logs to demonstrate compliance during inspections.
- Implement quality control checks for narrative clarity and completeness.
For example, in an immunology trial, sponsors introduced plain-language SUSAR summaries alongside CIOMS forms, improving EC understanding and avoiding requests for additional clarifications.
Regulatory Implications of Poor Ethics Committee Reporting
Failure to meet ethics committee SUSAR reporting requirements can have significant consequences:
- Inspection findings: Delayed or incomplete EC reporting is frequently cited as a compliance gap.
- Trial suspension: ECs may halt recruitment or ongoing participation until safety concerns are addressed.
- Regulatory escalation: Non-compliance may trigger regulatory inquiries or sanctions.
- Loss of trust: ECs play a protective role; poor reporting damages sponsor credibility.
In one MHRA inspection, trial suspension occurred due to repeated sponsor delays in notifying ECs about fatal SUSARs, highlighting the gravity of compliance failures.
Key Takeaways
SUSAR reporting to ethics committees is not just a regulatory obligation but an ethical imperative. To ensure compliance and participant protection, sponsors and investigators should:
- Report SUSARs to ECs within defined timelines, in parallel with regulatory authorities.
- Provide comprehensive CIOMS forms, narratives, and lay summaries as required.
- Adapt submissions to local EC requirements, while maintaining global consistency.
- Maintain clear documentation and quality control to demonstrate inspection readiness.
By embedding these practices, clinical trial teams can safeguard participants, enhance ethics committee oversight, and ensure compliance with global regulatory frameworks.